Home Antibody All anti-APP antibodies
|APP antibody was raised against an 18 amino acid peptide near the amino terminus of human APP.|
|Human, Mouse, Rat
||WB: 1 - 2 ug/ml, IHC: 2.5 ug/ml, IF: 20 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column
|Homo sapiens amyloid beta (A4) precursor protein (APP), transcript variant 1|
|AAA; ABETA; ABPP; AD1; APPI; CTFgamma; CVAP; PN-II; PN2|
|Accumulation of the amyloid-beta peptide (Abeta) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The beta-amyloid protein precursor (APP) is cleaved by one of two beta-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for ?-secretase to generate the 4 kDa amyloid-beta peptide (Abeta), which is deposited in the Alzheimer’s disease patients’ brains. Recently, Death Receptor 6 (DR6) was found to interact with an amino-terminal fragment of the Beta-amyloid protein (N-APP) in neurons, activating a caspase 6-dependent apoptotic event leading to axonal degeneration and pruning during development, suggesting that these two proteins are involved in neural development and may possibly play a role in Alzheimer’s disease.|
Delta-Notch Signaling Pathway
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of APP in mouse brain tissue lysate with APP antibody at (A) 1 and (B) 2 ug/ml.
Immunohistochemistry of APP in mouse brain tissue with APP antibody at 2.5 ug/ml.